
Indoco Remedies Ltd
NSE:INDOCO

Net Margin
Indoco Remedies Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
IN |
![]() |
Indoco Remedies Ltd
NSE:INDOCO
|
22.4B INR |
-1%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
676.4B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
367.9B USD |
24%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.7B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
181.7B CHF |
24%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
161.8B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
195.2B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
132.6B USD |
13%
|
Indoco Remedies Ltd
Glance View
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Indoco Remedies Ltd's most recent financial statements, the company has Net Margin of -0.6%.